PMID- 32241691 OWN - NLM STAT- MEDLINE DCOM- 20210429 LR - 20210429 IS - 1873-2496 (Electronic) IS - 1078-1439 (Linking) VI - 38 IP - 6 DP - 2020 Jun TI - Chromosomal deletion of 9p21 is linked to poor patient prognosis in papillary and clear cell kidney cancer. PG - 605.e1-605.e8 LID - S1078-1439(20)30063-6 [pii] LID - 10.1016/j.urolonc.2020.02.022 [doi] AB - BACKGROUND: The ongoing approval of adjuvant systemic therapy in high-risk kidney tumor will increase the demand for prognostic assessment in these tumors. 9p21 deletion has been suggested as a possible prognostic feature in clear cell kidney cancer. MATERIAL AND METHODS: To learn more on the prognostic relevance of 9p21 deletions in clear cell and other kidney tumors, 1,809 kidney tumor specimens were analyzed by dual-labeling fluorescence in situ hybridization (FISH) with probes for 9p21 and centromere 9 in a tissue microarray format. Results were compared to histologic tumor type, pT stage, grade, and patient outcome. RESULTS: A total of 1,341 (74%) of tumor samples had interpretable FISH results. 9p21 deletion was found in 4.4% of 894 clear cell, 5.1% of 197 papillary, and 4.2% of 71 chromophobe carcinomas. 9p21 deletions were not found in 112 oncocytomas and in 21 clear cell tubulo-papillary cancers. In clear cell carcinomas, 9p deletions were associated with advanced stage (P = 0.009) and nodal metastasis (P = 0.0067), but not with ISUP grade (P = 0.1039) and distant metastasis (P = 0.4809). Also, in papillary carcinomas, 9p deletions were associated with advanced stage (P = 0.0008) and nodal metastasis (P = 0.0202) but not with ISUP grade (0.0904) and distant metastasis (P = 0.2022). Follow-up data were available for 789 clear cell and 177 papillary cancers. In both tumor entities, 9p21 deletions were associated with shortened overall survival, tumor-specific death, and progression-free survival in univariate analysis (P < 0.02 each). In a multivariate analysis, 9p21 deletion was an independent predictor of early tumor recurrence (P = 0.04). CONCLUSION: 9p21 deletions, 9p21 deletions identify a small subset of aggressive renal carcinomas. 9p deletion assessment may be clinically useful to identify high-risk renal cell carcinomas. CI - Copyright (c) 2020 Elsevier Inc. All rights reserved. FAU - Eichenauer, Till AU - Eichenauer T AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Simmendinger, Luca AU - Simmendinger L AD - Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Kluth, Martina AU - Kluth M AD - Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Chirico, Victoria AU - Chirico V AD - Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Luebke, Andreas M AU - Luebke AM AD - Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Hoflmayer, Doris AU - Hoflmayer D AD - Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Hinsch, Andrea AU - Hinsch A AD - Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Jacobsen, Frank AU - Jacobsen F AD - Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Hube-Magg, Claudia AU - Hube-Magg C AD - Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Moller-Koop, Christina AU - Moller-Koop C AD - Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Dahlem, Roland AU - Dahlem R AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Fisch, Margit AU - Fisch M AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Rink, Michael AU - Rink M AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Riechardt, Silke AU - Riechardt S AD - Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Tsourlakis, Maria Christina AU - Tsourlakis MC AD - Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Buscheck, Franziska AU - Buscheck F AD - Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Bernreuther, Christian AU - Bernreuther C AD - Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Clauditz, Till AU - Clauditz T AD - Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Lebok, Patrick AU - Lebok P AD - Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Simon, Ronald AU - Simon R AD - Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Electronic address: R.Simon@uke.de. FAU - Sauter, Guido AU - Sauter G AD - Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Wilczak, Waldemar AU - Wilczak W AD - Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Fraune, Christoph AU - Fraune C AD - Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. LA - eng PT - Journal Article DEP - 20200330 PL - United States TA - Urol Oncol JT - Urologic oncology JID - 9805460 SB - IM MH - Aged MH - Aged, 80 and over MH - Carcinoma, Renal Cell/*genetics/*mortality MH - *Chromosome Deletion MH - Chromosomes, Human, Pair 9/*genetics MH - Humans MH - Kidney Neoplasms/*genetics/*mortality MH - Prognosis MH - Survival Rate OTO - NOTNLM OT - 9p21 deletion OT - Fluorescence in situ hybridization OT - Prognosis OT - Renal cell cancer OT - Tissue microarray EDAT- 2020/04/04 06:00 MHDA- 2021/04/30 06:00 CRDT- 2020/04/04 06:00 PHST- 2019/08/19 00:00 [received] PHST- 2020/01/07 00:00 [revised] PHST- 2020/02/19 00:00 [accepted] PHST- 2020/04/04 06:00 [pubmed] PHST- 2021/04/30 06:00 [medline] PHST- 2020/04/04 06:00 [entrez] AID - S1078-1439(20)30063-6 [pii] AID - 10.1016/j.urolonc.2020.02.022 [doi] PST - ppublish SO - Urol Oncol. 2020 Jun;38(6):605.e1-605.e8. doi: 10.1016/j.urolonc.2020.02.022. Epub 2020 Mar 30.